{"id":"mat2203","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MAT2203 encapsulates amphotericin B, a polyene antifungal agent, within proprietary lipid nanoparticles to enhance bioavailability and reduce nephrotoxicity and infusion-related reactions associated with conventional amphotericin B formulations. The nanoparticle delivery system allows for improved targeting to fungal pathogens while minimizing exposure to healthy tissues.","oneSentence":"MAT2203 is a lipid nanoparticle formulation of amphotericin B designed to improve drug delivery and reduce toxicity in fungal infections.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:11.294Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Invasive fungal infections (including aspergillosis and candidiasis)"},{"name":"Cryptococcal meningitis"}]},"trialDetails":[{"nctId":"NCT02629419","phase":"PHASE2","title":"CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis","status":"COMPLETED","sponsor":"Matinas BioPharma Nanotechnologies, Inc.","startDate":"2016-09-27","conditions":"Candidiasis, Chronic Mucocutaneous","enrollment":4},{"nctId":"NCT04031833","phase":"PHASE1, PHASE2","title":"Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)","status":"COMPLETED","sponsor":"Matinas BioPharma Nanotechnologies, Inc.","startDate":"2019-10-24","conditions":"Cryptococcal Meningitis","enrollment":178},{"nctId":"NCT05541107","phase":"PHASE3","title":"Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3","status":"UNKNOWN","sponsor":"Matinas BioPharma Nanotechnologies, Inc.","startDate":"2023-01","conditions":"Cryptococcal Meningitis","enrollment":270},{"nctId":"NCT03187691","phase":"PHASE2","title":"Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia","status":"WITHDRAWN","sponsor":"Matinas BioPharma Nanotechnologies, Inc.","startDate":"2019-08","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia","enrollment":""},{"nctId":"NCT03167957","phase":"PHASE2","title":"Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis","status":"WITHDRAWN","sponsor":"Matinas BioPharma Nanotechnologies, Inc.","startDate":"2019-12","conditions":"Vulvovaginal Candidiases, Yeast Infection, Vulvovaginitis","enrollment":""},{"nctId":"NCT03196921","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Oral Encochleated Amphotericin B for the Treatment of Cryptococcal Infection","status":"WITHDRAWN","sponsor":"Matinas BioPharma Nanotechnologies, Inc.","startDate":"2018-10-01","conditions":"Cryptococcal Infections","enrollment":""},{"nctId":"NCT02971007","phase":"PHASE2","title":"Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)","status":"COMPLETED","sponsor":"Matinas BioPharma Nanotechnologies, Inc.","startDate":"2016-11","conditions":"Vulvovaginitis, Yeast Infection, Yeast Infection Vaginal","enrollment":137}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["oral amphotericin B","cAMB"],"phase":"phase_3","status":"active","brandName":"MAT2203","genericName":"MAT2203","companyName":"Matinas BioPharma Nanotechnologies, Inc.","companyId":"matinas-biopharma-nanotechnologies-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MAT2203 is a lipid nanoparticle formulation of amphotericin B designed to improve drug delivery and reduce toxicity in fungal infections. Used for Invasive fungal infections (including aspergillosis and candidiasis), Cryptococcal meningitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}